bluebird bio, Inc. (BLUE) |
|
3.04 0.02 (0.66%)
|
09-29 16:00 |
|
Open: |
3.07 |
Pre. Close: |
3.02 |
|
High:
|
3.16 |
Low:
|
2.97 |
|
Volume:
|
2,597,664 |
Market Cap:
|
325(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:15 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.18 One year: 4.66 |
| Support: |
Support1: 2.92 Support2: 2.42 |
| Resistance: |
Resistance1: 3.58 Resistance2: 3.99 |
| Pivot: |
3.2  |
| Moving Average: |
MA(5): 3.04 MA(20): 3.32
MA(100): 3.59 MA(250): 4.98 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 15.9 %D(3): 15.9 |
| RSI: |
RSI(14): 36 |
| 52-week: |
High: 8.57 Low: 2.77 |
| Average Vol(K): |
3-Month: 4,224 (K) 10-Days: 2,813 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLUE ] has closed above bottom band by 25.2%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.16 - 3.18 |
3.18 - 3.2 |
|
Low:
|
2.92 - 2.95 |
2.95 - 2.97 |
|
Close:
|
3.01 - 3.04 |
3.04 - 3.07 |
|
Company Description |
|
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Sun, 01 Oct 2023
Bluebird Bio Receives Mixed Ratings from Analysts, Shows Signs of ... - Best Stocks
Fri, 29 Sep 2023
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus ... - MarketBeat
Tue, 26 Sep 2023
Is bluebird bio Inc (BLUE) Stock About to Get Hot Tuesday? - InvestorsObserver
Mon, 25 Sep 2023
Sickle Cell Disease Finally Getting its Due - Managed Healthcare Executive
Wed, 20 Sep 2023
7 Top Gene-Editing Stocks to Buy - WTOP
Wed, 13 Sep 2023
Where Does Wall Street Think bluebird bio Inc (BLUE) Stock Will Go? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
107 (M) |
|
% Held by Insiders
|
9.14e+007 (%) |
|
% Held by Institutions
|
0.8 (%) |
|
Shares Short
|
28,840 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3321e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
466.4 |
|
Return on Equity (ttm)
|
-14 |
|
Qtrly Rev. Growth
|
9.4e+006 |
|
Gross Profit (p.s.)
|
380.21 |
|
Sales Per Share
|
-43.99 |
|
EBITDA (p.s.)
|
-2.65849e+008 |
|
Qtrly Earnings Growth
|
-0.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-293 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.07 |
|
Price to Cash Flow
|
1.04 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.604e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
